Physician profile
Mei He
NPI 1790982395
$4,696.87
in general payments reported to CMS, 2019-2025
20 companies · $870 in 2025
The $870 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $121 · 2021: $29.58 · 2022: $164 · 2023: $498 · 2024: $3,014 · 2025: $870.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,943 · Travel and Lodging: $1,440.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,942.72 |
| Travel and Lodging | $1,439.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $2,954.15 | 2023-2025 | Inspire |
| Abbvie INC. | $538.80 | 2021-2025 | |
| Itamar Medical INC | $322.40 | 2024-2025 | Watchpatone |
| Teva Pharmaceuticals USA, INC. | $125.26 | 2019-2023 | Austedo Xr |
| Sk Life Science, INC. | $122.61 | 2023-2025 | |
| Abbott Laboratories | $92.82 | 2023-2024 | Infinity |
| Lundbeck LLC | $85.83 | 2022-2023 | Rexulti, Vyepti |
| Lilly USA, LLC | $63.29 | 2019-2025 | Kisunla |
| Merz Pharmaceuticals, LLC | $55.28 | 2025 | Xeomin |
| Acadia Pharmaceuticals INC | $52.54 | 2024 | Nuplazid |
| Argenx US, INC. | $50.45 | 2024 | |
| Amneal Pharmaceuticals LLC | $41.05 | 2022-2023 | Rytary |
| Ge Healthcare | $36.26 | 2022-2024 | |
| Neurelis, INC. | $34.76 | 2024 | Valtoco |
| Jazz Pharmaceuticals INC. | $32.82 | 2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impel Pharmaceuticals INC. | $25.10 | 2022 | |
| Allergan, INC. | $17.38 | 2021 | |
| Alexion Pharmaceuticals, INC. | $16.42 | 2023 | Ultomiris |
| Pfizer INC. | $15.20 | 2024 | |
| Novartis Pharmaceuticals Corporation | $14.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mei He listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.